<DOC>
	<DOCNO>NCT02319629</DOCNO>
	<brief_summary>Risk factor cholelithiasis rapid weight loss bariatric surgery change gallbladder function secondary surgery . Many observational study support fact , high incidence 28 % -71 % gastric bypass surgery ( RYGB ) report . According another publication , incidence gallbladder diseases 5-36 % jejunoileal bypass surgery 2.8-36 % gastric bypass surgery .</brief_summary>
	<brief_title>Preventive Therapy With Ursodiol Reduce Incidence Gallstones Formation Patients After Bariatric Surgery</brief_title>
	<detailed_description>Study format : Prospective , randomize , blind study . 266 candidate sleeve gastrectomy gastric bypass surgery due morbid obesity BMI range 40-50 age 18-65 study . The patient randomly divide two group ( accord last digit identity card number ) : 1 . Treatment group receive preventive therapy Ursodiol 600 mg per day day 10 surgery ( first routine visit surgery ) six month formation gallstone . 2 . Placebo group receive placebo day 10 surgery ( first routine visit surgery ) six month formation gallstone .</detailed_description>
	<mesh_term>Obesity , Morbid</mesh_term>
	<mesh_term>Gallstones</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<criteria>Candidates sleeve gastrectomy gastric bypass surgery due morbid obesity BMI range 40 to50 . Aged 18 65 . No presence gallstone . Patients sign consent form . Minors , Pregnant woman , Age 65 , Sensitive Ursodiol , Gallstones , Biliary tract pathology , Gallbladder wall thickening , Patients cholecystectomy , Patients participate another clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Morbid obesity ,</keyword>
	<keyword>Cholelithiasis</keyword>
	<keyword>Bariatric surgery</keyword>
	<keyword>Ursodiol</keyword>
</DOC>